Recently, CD13 has been identified as a novel cell surface marker for semiquiescent CSCs in human HCC cell lines and clinical specimens, and CD13+ CSCs were relative to a hypoxic marker in clinical HCC sample. This evidence concerns the gene ANPEP and hepatocellular carcinoma.